Patents by Inventor Zachary R. MOORE

Zachary R. MOORE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumor-selective combination therapy
    Patent number: 10576096
    Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 3, 2020
    Assignees: The Board of Regents of the University of Texas System, The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Lifen Cao, Jinming Gao, Xiumei Huang, Xiuquan Luo, Xinpeng Ma, Zachary R. Moore, Elizabeth I. Parkinson
  • Tumor-selective combination therapy
    Patent number: 10272099
    Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: April 30, 2019
    Assignees: The Board of Regents of the University of Texas System, The Board of Trustees of the University of Illinois.
    Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Lifen Cao, Jinming Gao, Xiumei Huang, Xiuquan Luo, Xinpeng Ma, Zachary R. Moore, Elizabeth I. Parkinson
  • TUMOR-SELECTIVE COMBINATION THERAPY
    Publication number: 20180099002
    Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
    Type: Application
    Filed: December 6, 2017
    Publication date: April 12, 2018
    Applicants: The Board of Regents of the University of Texas System, The Board of Trustees of the University of Illinois
    Inventors: Paul J. HERGENROTHER, David A. BOOTHMAN, Joseph S. BAIR, Lifen CAO, Jinming GAO, Xiumei HUANG, Xiuquan LUO, Xinpeng MA, Zachary R. MOORE, Elizabeth I. PARKINSON
  • TUMOR-SELECTIVE COMBINATION THERAPY
    Publication number: 20160030457
    Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
    Type: Application
    Filed: April 8, 2014
    Publication date: February 4, 2016
    Applicants: The Board of Regents of the University of Texas System, The Board of Trustees of University of Illinois
    Inventors: Paul J. HERGENROTHER, David A. BOOTHMAN, Joseph S. BAIR, Lifen CAO, Jinming GAO, Xiumei HUANG, Xiuquan LUO, Xinpeng MA, Zachary R. MOORE, Elizabeth I. PARKINSON